Synektik (SNTP) Q3 2024 earnings summary

Executive summary

• Revenue for the nine months ended June 30, 2024, increased by 55% year-over-year to PLN 482.98 million, with net profit up 74% to PLN 63.65 million.

• Strong growth in both medical equipment and radio-pharmaceuticals segments, with recurring revenues up 71% year-over-year.

• EBITDA rose 69% year-over-year to PLN 111.04 million, with EBITDA margin improving to 23%.

Financial highlights

• Operating profit for the nine months was PLN 82.65 million, up from PLN 44.85 million year-over-year.

• Net cash from operating activities reached PLN 65.02 million, with a net increase in cash of PLN 14.00 million.

• Earnings per share for the period were PLN 7.46, compared to PLN 4.29 a year earlier.

• Book value per share increased to PLN 20.09 from PLN 15.73 at September 30, 2023.

Outlook and guidance

• Management expects continued growth in medical equipment, IT, and service sales, supported by new product launches and increased healthcare spending.

• Expansion in surgical robotics and radio-pharmaceuticals, with new markets and products targeted.

• No financial forecasts were published for the fiscal year.